参考文献/References:
[1] 段薇,杜建玲,李昌臣.TSHR与自身免疫性甲状腺疾病关系的研究进展.国外医学内分泌学分册,2003,23(1):40-42.
[2] Tomer Y, Barbesino G, Keddache M, et al. Mapping of a major sus-ceptibility locus for Graves’ disease (GD-1) to chromosome 14q31. J Clin Endocrinol Metab, 1997, 82(5):1645-1648.
[3] AkamizuT, MoriyamaK, MiuraM, et al Characterization of recombinant monoclonal antithyrotropin receptor antibodies (TSHRAbs) derived from lymphocytes of patients with Graves’"disease:epitope and binding study of two stimulatory TSHRAbs. Endocrinology, 1999, 140(4):1594-1601.
[4] Marians RC, Ng L, Blair HC, et al. Defining thyrotropin-dependent and -independent steps of thyroid hormone synthesis by using thy-rotropin receptor-null mice. Proc Natl Acad Sci USA, 2002, 99(24):15776-15781.
[5] García-Jiménez C, Santisteban P. TSH signalling and cancer. Arq Bras Endocrinol Metabol, 2007, 51(5):654-671.
[6] Hoffmann S, Maschuw K, Hassan I, et al. Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid caneer cells. Endocrine, 2006, 30(1):129-138.
[7] 刘翔,高明.促甲状腺素抗氧化传导通路与甲状腺乳头状癌侵袭力的关系.中华耳鼻咽喉头颈外科杂志,2009,44(4):287-291.
[8] Rivas M, Santisteban P. TSH-activated signaling pathways in thy-roid tumorigenesis. Mol Cell Endocrinol, 2003, 213(1):31-45.
[9] Xing M, Usadel H, Cohen Y, et al. Methylation of the thyroid-stim-ulating hormone receptor gene in epithelial thyroid tumors:a marker of malignancy and a cause of gene silencing. Cancer Res, 2003,63(9):2316-2321.
[10] Yokomori N, Tawata M, Saito T, et al. Regulation of the rat thy-rotropin receptor gene by the methylation-sensitive transcription factor GA-binding protein. Mol Endocrinol, 1998,12(8):1241-1249.
[11] Roger PP,van Staveren WC,Coulonval K,et al.Signal transduction in the human thyrocyte and its perversion in thyroid tumors.Mol Cell Endocrinol,2010,321 (1):3-19.
[12] Rivas M,Santisteban P.TSH-activated signaling pathways in thy-roid tumorigenesis.Mol Cell Endocrinol,2003,213(1):31-45.
[13] Derwahl M,Kuemmel M,Goretzki P.et al.F-xpression of the human TSH receptor in a human thyroid carcinoma cell line that lacks an endogenous TSH receptor:growth inhibition by cAMP.Biochem Biophys Res Commun,1993,191(3):1131-1138.
[14] Shirokawa JM,Elisei R,Knauf JA,et al.Conditional apoptosis in-duced by oncogenic ras in thyroid cells.Mol Endocrinol,2000,14(11):1725-1738.
[15] Dumaz N,Marais R.Irilegraling signals between cAMP and the RAS/RAF/MKK/ERK signalling pathways.Based on the anniver-sary prize of the Gesellschaft für Biochemie und Molekularhiologie Lecture delivered on 5 July 2003 at the Special FERS Meeting in Brussels.FEES J,2005,272(14):3491-3504.
[16] De Gregorio G,Coppa A,Cosentino C,et al.The p85 regulatory subunit of PT3K mediates TSH-cAMP-PKA growth and survival signals.Oncogene,2007,26(14):2039-2047.
[17] Simon D,Körher G,Krausnh M,et al.Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer:final results of a pilot study.Rur J Nucl Med Mol Imaging,2002,29(6):775-782.
[18] 侯莎莎,千辉,冯方,等.重组质粒hTSHR转染低分化甲状腺癌细胞株后对摄碘能力及特异性基因表达的影响.中华核医学杂志,2011,31(2):92-96.
[19] Paron I,D’Amhrosio C,Scaloni A,et al.A differential proteomic approach to identify proteins associated with thyroid cell Iransfor-mation.J Mol Endoorinol,2005,34(1):199-207.
[20] Kim HJ,Chae HZ,Kim YJ,et al.Preferenlial elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues.Cell Biol Toxicol,2003,19(5):285-298.
[21] Park JH,Kim YS,Lee HL,et al.Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung.Respirology,2006,11 (3):269-275.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[4]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[5]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[6]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[7]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[8]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[9]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[10]刘鹏杰,唐铭,邓智勇,等.131I治疗儿童分化型甲状腺癌期间出现低钙血症伴癫痫发作一例[J].国际放射医学核医学杂志,2015,39(4):352.[doi:10.3760/cma.j.issn.1673-4114.2015.04.017]
[11]侯仁花,吕中伟.生长抑素受体显像剂99mTc-depreotide的研究进展[J].国际放射医学核医学杂志,2008,32(1):15.
HOU Ren-hua,LÜ,Zhong-wei.The progress of a new somatostatin receptor agent 99mTc-depreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(2):15.
[12]何蕊,朱高红.甲状腺髓样癌靶向治疗的研究进展[J].国际放射医学核医学杂志,2018,(2):154.[doi:10.3760/cma.j.issn.1673-4114.2018.02.010]
He Rui,Zhu Gaohong.Research status of medullary thyroid carcinoma targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):154.[doi:10.3760/cma.j.issn.1673-4114.2018.02.010]